N°05 WRAITH
Defend
Hard-training health support.
- Vitamin D3 4
- Quercetin Phytosome 500 mg
- Vitamin C 1
In Development
Formula direction is visible.
Final records are not.
This product record shows current formula direction while sourcing, label artwork, sample evaluation, testing requirements, and launch readiness are still being finalized.
What to Expect
- Daily use
Defend is a pack architecture for hard-training health support, not an acute-feel product.
- Repeated use
Relevant markers are bloodwork, diet, training load, and consistency, not day-one sensation.
Ingredients
Vitamin D3 4,000 IU at reference dose
- Form
- Cholecalciferol in softgel
- Mechanism
- Foundational immune and musculoskeletal support nutrient, especially when status is low. [1]
- Evidence Summary
- Bergman 2012 supports vitamin D for respiratory-tract infection risk in pooled analysis, but effects depend strongly on baseline status and study design.
- Why This Dose
- 4,000 IU is a high but common daily supplemental dose used to support status in larger hard-training adults.
- Why This Form
- Cholecalciferol is the standard supplemental D3 form and is best delivered with fat.
- Limitations
- Vitamin D is included for nutrient support, not for disease or testosterone claims in Defend.
Quercetin Phytosome 500 mg
- Form
- Quercefit by Indena
- Mechanism
- Supports immune and inflammatory-response signaling with improved quercetin bioavailability. [2] [3] [4]
- Evidence Summary
- Riva 2019 supports the PK rationale for phytosome delivery. The audit cites Rondanelli 2022 and Di Pierro 2021 as clinical anchors.
- Why This Dose
- 500 mg matches the audit's selected clinical dose.
- Why This Form
- Phytosome delivery is the form decision; generic quercetin would weaken the bioavailability case.
- Limitations
- Not positioned for antiviral or disease-prevention claims.
Vitamin C 1,000 mg
- Form
- Ascorbic acid
- Mechanism
- Supports immune function and antioxidant defenses under intense training load. [5]
- Evidence Summary
- Vitamin C evidence is strongest for specific stress and athlete contexts, not broad disease-prevention claims.
- Why This Dose
- 1,000 mg is the dose used in the athlete-support logic and keeps the claim simple.
- Why This Form
- Ascorbic acid is direct, inexpensive, and studied.
- Limitations
- Antioxidant support is not the same as eliminating inflammation or accelerating all recovery.
Zinc 25 mg elemental
- Form
- Zinc bisglycinate, TRAACS preferred
- Mechanism
- Supports immune function and zinc status during heavy training. [6] [7]
- Evidence Summary
- Science 2012 and Cochrane 2024 are the audit anchors for immune support. Prasad 1996 is secondary background, not the Defend claim.
- Why This Dose
- 25 mg elemental is meaningful without pushing toward the chronic upper-limit concerns of higher-dose zinc formulas.
- Why This Form
- Bisglycinate is chosen for tolerability and absorption.
- Limitations
- Not a stand-alone testosterone ingredient in this product.
TUDCA 500 mg
- Form
- Tauroursodeoxycholic acid
- Mechanism
- Supports bile-flow and hepatic stress-response pathways. [8] [9]
- Evidence Summary
- Crosignani 1996 tested 500 to 1,500 mg/day and reported liver-enzyme changes. Ma 2016 compared TUDCA with UDCA in primary biliary cholangitis.
- Why This Dose
- 500 mg is the floor of the clinical range and the best pack-feasible choice for a support product.
- Why This Form
- TUDCA is the studied molecule; no proprietary form is needed.
- Limitations
- Defend does not claim to address liver injury.
Silymarin 420 mg silymarin equivalent
- Form
- Siliphos, silybin-phytosome
- Mechanism
- Supports hepatic antioxidant pathways and liver-enzyme health markers. [10] [11]
- Evidence Summary
- Wei 2024 and Kim 2024 meta-analyses support the hepatic rationale, but the populations are clinical and claims stay structure/function.
- Why This Dose
- 420 mg silymarin equivalent matches the established hepatic-support dose cited in the audit.
- Why This Form
- Siliphos is selected because silybin bioavailability is otherwise poor.
- Limitations
- This is not a claim to diagnose, treat, cure, or prevent liver disease.
Berberine HCl 1,000 mg
- Form
- 97 percent or greater, Berberis aristata
- Mechanism
- Supports healthy lipid and glucose metabolism through AMPK and LDL-receptor related pathways. [12] [13] [14]
- Evidence Summary
- Blais 2023 and Lan 2015 support lipid effects; Yin 2008 is a foundational glucose RCT in diabetes and is used only as mechanism context.
- Why This Dose
- 1,000 mg/day captures the lower end of the clinical range while improving tolerability versus 1,500 mg.
- Why This Form
- Berberine HCl is the human-evidence form. Dihydroberberine may be interesting but has a thinner RCT base.
- Limitations
- Can cause GI upset and is not designed to diagnose, treat, cure, or prevent diabetes or dyslipidemia.
Omega-3 2,000 mg, providing 1,400 mg EPA and 600 mg DHA
- Form
- EPA-rich triglyceride form softgel
- Mechanism
- Supports triglyceride metabolism and cardiovascular health. [15] [16]
- Evidence Summary
- Wang 2024 supports a dose-response relationship for triglyceride reduction; Khan 2021 supports EPA-forward cardiovascular outcome context.
- Why This Dose
- 2 g/day total omega-3 is the practical clinical floor for this pack and requires softgels.
- Why This Form
- Triglyceride form is selected for bioavailability. IFOS or equivalent purity documentation is expected before launch.
- Limitations
- Omega-3 is not a substitute for medical management of lipids or cardiovascular risk.
Supplement Facts
Pending
Supplement Facts will be added before this product ships.
Directions
- Serving Size
- 8 capsules plus 2 softgels at the 200 lb reference dose
- Dosing Protocol
- 151 to 180 lb uses 7 capsules, 4,000 IU D3, and 875 mg berberine. 181 to 210 lb uses 8 capsules, 4,000 IU D3, and 1,000 mg berberine. 211 lb and above uses 8 capsules, 5,000 IU D3, and 1,000 mg berberine.
- Timing
- With the largest fat-containing meal.
Third-Party Testing
WRAITH uses third-party testing and lot-level accountability as part of the testing standard. Identity, potency, heavy metals, microbiology, and sports nutrition adulterant panels are reviewed where applicable.
Testing documentation will be published by lot as products become available.
Why We Built It This Way
Product Hypothesis
Hard training creates a broader health-support problem than a multivitamin can solve. Defend uses a pack architecture because the relevant clinical doses do not fit into a minimalist capsule count.
Mechanism Map
- Hepatic axis: TUDCA and silymarin support bile-flow and hepatocyte antioxidant pathways.
- Metabolic axis: berberine supports healthy lipid and glucose metabolism already within normal range.
- Immune axis: vitamin D3, vitamin C, zinc, and quercetin phytosome support immune function during hard training.
- Cardiovascular axis: EPA-rich omega-3 supports triglyceride and cardiovascular health parameters.
- Oxidative axis: vitamin C, silymarin, quercetin, and omega-3 address different parts of oxidative load without pretending to erase training stress.
Dosing Architecture
Defend uses a weight-tiered protocol as a pragmatic pack architecture, not because every ingredient has strict mg/kg evidence. The reference serving anchors the strongest clinical-dose logic.
Form Rationale
Several ingredients require specific forms to make the formula defensible: Quercefit, Siliphos, berberine HCl, zinc bisglycinate, cholecalciferol, and triglyceride-form EPA-rich omega-3.
What This Does Not Do
- Not designed or marketed for drug-exposure mitigation, nor to diagnose, treat, cure, or prevent liver, cardiovascular, lipid, or glucose disorders. Users with diagnosed conditions should speak with a clinician.
- Not a multivitamin.
- Not a substitute for bloodwork, medical care, sleep, diet, or training management.
Evidence Limitations
- Many cited studies are in clinical or risk-enriched populations; customer-facing claims remain general structure/function claims.
- Supplements are not a substitute for clinical care for established cardiovascular conditions, hematocrit abnormalities, arrhythmia concerns, or organ injury.
- The exact multi-ingredient pack has not been tested as a single formula.
- Chromium
Excluded because berberine covers the glucose-metabolism territory with a stronger evidence base.
- Cinnamon
Excluded because effect sizes are inconsistent and cassia coumarin content conflicts with the hepatic-support architecture.
- Digestive enzymes
Rejected as non-essential label-padding without meaningful outcome evidence in healthy hard-training adults.
- ALA
Excluded as redundant with silymarin and berberine on the glucose and oxidative axes, with poorer stability economics.
- Hormonal support ingredients
Tongkat Ali, boron, and ashwagandha are excluded to preserve Restore and Edge territory.
FAQ
Is Defend a medical product?
No. Defend is a hard-training health support pack and is not designed, labeled, or marketed for drug exposure or medical use.
Why so many capsules?
The clinical doses do not fit a minimalist capsule count. Lowering the count would mean lowering the standard.
References
- [1] Bergman P et al. Vitamin D and respiratory tract infections: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2013. PMID: 23242238.
- [2] Riva A et al. Improved oral absorption of quercetin from Quercefit. Journal of Dietary Supplements. 2019. PMID: 30328046.
- [3] Rondanelli M et al. Quercetin phytosome and immune function evidence cited in Defend audit. Life. 2022. DOI: 10.3390/life12010066.
- [4] Di Pierro F et al. Quercetin phytosome clinical evidence cited in Defend audit. 2021. PMID: 34135619.
- [5] Hemila H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database of Systematic Reviews.
- [6] Science M et al. Zinc for the treatment of the common cold: systematic review and meta-analysis. CMAJ. 2012. PMID: 22566526.
- [7] Cochrane Review. Zinc for prevention and treatment of the common cold. CD014914. 2024.
- [8] Crosignani A et al. Tauroursodeoxycholic acid for chronic cholestatic liver disease: dose-response RCT. Dig Dis Sci. 1996. PMID: 8674405.
- [9] Ma X et al. TUDCA versus UDCA in primary biliary cholangitis: multicenter randomized trial. Medicine. 2016.
- [10] Wei J et al. Silymarin in NAFLD/NASH: meta-analysis of randomized controlled trials. Ann Hepatol. 2024. PMID: 38579127.
- [11] Kim et al. Silymarin effects on liver enzymes: systematic review and meta-analysis. 2024. PMC10946183.
- [12] Blais P et al. Berberine and lipid profile: systematic review and meta-analysis. 2023. PMID: 37183391.
- [13] Lan J et al. Meta-analysis of berberine in treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015.
- [14] Yin J et al. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008.
- [15] Wang et al. Dose-response relationship between omega-3 fatty acids and triglycerides. J Am Heart Assoc. 2024. DOI: 10.1161/JAHA.123.029512.
- [16] Khan SU et al. Effect of omega-3 fatty acids on cardiovascular outcomes: systematic review and meta-analysis. eClinicalMedicine. 2021. PMC8413259.
California Prop 65
WARNING:
Consuming this product can expose you to chemicals including lead and cadmium, which are known to the State of California to cause cancer and birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov/food.